Company intelligence / Profile preview
TargTex
Torres Vedras, Portugaltargtex.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
TargTex’s lead candidate TTX101, a hydrogel nanoformulation to be used as a single-dose adjunct therapy in surgical resection of glioblastoma, has demonstrated a survival advantage in preclinical rodent models and has received FDA Orphan Drug Designation for malignant gliomas[1].
- Therapeutic areas
- Oncology
- Modalities
- Hydrogel-based drug delivery therapySmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Nanoform (nanoformulation technology collaboration)
Beyond the preview
Go deeper on TargTex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TargTex.